# Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

> **NCT05745532** · EARLY_PHASE1 · RECRUITING · sponsor: **Shenzhen Hemogen** · enrollment: 10 (estimated)

## Conditions studied

- β-thalassemia

## Interventions

- **BIOLOGICAL:** β-globin restored autologous hematopoietic stem cells

## Key facts

- **NCT ID:** NCT05745532
- **Lead sponsor:** Shenzhen Hemogen
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745532, "Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05745532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*